



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Charles G. Cochrane et al.

Serial No.

08/419,824

Filed:

April 11, 1995

Art Unit: 1811

For:

PULMONARY SURFACTANT PROTEINS

AND RELATED POLYPEPTIDES

Examiner:

Patrick R. Delaney

<u>IENT</u>

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

In response to the Requirement for Restriction dated 7 January 1997 in the above-identified application, the applicants provisionally elect for prosecution the claims of Group I, i.e. claims 1-33 drawn to compounds and compositions. The election is made with traverse. Reconsideration of the restriction requirement is requested inasmuch as the compounds and compositions of Group I are related sufficiently closely to the methods of use contemplated by the claims of Group II. It is believed that both groups of claims can be conveniently searched at the same time.

Further, and in response to the requirement to elect a single disclosed species, applicants provisionally elect for prosecution at this time the species

KLLLLKLLLKLLLK, i.e., the species defined by claim 9 and the corresponding pulmonary surfactant defined by claim 22.

Claims 1-7-read-on-claim-9. Claims 8, 12-17, 21 and 25-33 read on claim 22. An early action on the merits is solicited.

Respectfully submitted,

 $\hat{\mathbf{B}}\mathbf{v}$

Talivaldis Cepuritis (Reg. No. 2

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606

(312) 580-1180

3/27/97



CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO RESTRICTION REQUIREMENT is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on March 5, 1997.

Talivaldis Cepuritis (Reg. No. 20,818)